Abstract: Cervical cancer is a top leading cause of cancer deaths among Chinese women. Human papillomavirus infection is the essential factor in the development of nearly all cases of cervical cancer. The virus-like particle （VLP） derived from L1 gene coded by HPV genome induces the neutralization, as a result, the administration of VLP is effective against the infection of an HPV genotype. Since two HPV genotypes，i.e.，HPV16 and 18 are most prevalent in the cervical cancer，VLPs of both genotypes were developed as prophylactic vaccine for cervical cancer. So far，the clinical trial of HPV vaccines from two medical manufacturers showed safe，and more importantly, effective in the disease control of low grade cervical intraepithelial neoplasia, the pre-stage of cervical tumorgenesis. Based on the prospective effect from vaccination，the developed countries were in consideration for adjusting the control policy for cervical cancer.

Key words: Papillomavirus vaccines, Uterine cervical neoplasms, Human papillomavirus